You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
The decision comes after Myriad requested expanded coverage for women with breast cancer seeking information about extending endocrine therapy.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
The Medicare Administrative Contractor will provide limited coverage for the RNA gene expression test that helps rule out primary cutaneous melanoma.
The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.